+302.0%
IREN vs MRNA
+153.9%
+148.1%
-84.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -18.0% | -2.2% | -15.8% | -17.8% |
| 7D | -34.9% | -12.7% | -22.2% | -34.0% |
| 30D | -57.5% | -20.7% | -36.9% | -56.5% |
| 3M | -72.3% | +46.3% | -118.5% | -73.3% |
| 6M | -77.6% | +305.2% | -382.8% | -83.2% |
| YTD | -68.7% | +561.2% | -629.9% | -79.4% |
| 1Y | -72.8% | +772.1% | -844.9% | -83.3% |
| 3Y | +302.0% | +147.0% | +155.1% | +251.2% |
| All | +302.0% | +153.9% | +148.1% | +251.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling